Other

Upneeq

FDA-approved eye drops for non-surgical eyelid ptosis correction

시술 시간

1분 (점안)

다운타임

0일

권장 횟수

매일1회 (지속 사용)

이 치료에 대해

Upneeq (oxymetazoline HCl 0.1%) by RVL Pharmaceuticals is the world's first FDA-approved prescription eye drop for acquired ptosis. As an alpha-2 adrenergic agonist, it contracts the Müller's muscle to lift the upper eyelid by approximately 1mm.

Non-surgical "eye-opening" effect for age-related ptosis and Botox-induced drooping. Once-daily application.

작용 기전

Oxymetazoline 0.1% binds alpha-2 adrenergic receptors on Müller's muscle (superior tarsal muscle), inducing smooth muscle contraction to lift the upper eyelid by ~1mm. Unlike Botox, this "promotes contraction" rather than causing paralysis. Effect onset within 15 minutes, lasting 6-8 hours.

적응증

일반 적응증(상세 설명 참고)

기대 효과

Average 1mm upper eyelid lift from first use. Safety and efficacy confirmed in clinical trials. Sustained with daily use. Also effective for Botox-induced ptosis.

임상 근거

FDA Approval (RVL Pharmaceuticals) (2020)

Upneeq (oxymetazoline HCl 0.1%): FDA Approval for Acquired Blepharoptosis. FDA

해당 연구에서 임상적 개선이 보고되었습니다(자세한 내용은 원문 논문 참조).

Bacharach J, Lee WW, Harrison AR, et al. (2021)

A randomized, controlled trial of oxymetazoline hydrochloride 0.1% for the treatment of acquired blepharoptosis. Ophthal Plast Reconstr Surg

해당 연구에서 임상적 개선이 보고되었습니다(자세한 내용은 원문 논문 참조).

위험 및 부작용

Mild ocular irritation (immediately after application). Potential rebound ptosis with abrupt discontinuation. Minimal effect on IOP but caution in glaucoma patients. Avoid concurrent decongestant use. Prescription required.

이 치료에 관심이 있으신가요?

AI 피부 진단으로 현재 피부 상태를 확인해 보세요

AI 피부 진단 받기 예약하기

다른 치료 보기

LaserPicoSure Pro자세히 보기 LaserFractional Laser자세히 보기 LaserPhotofacial IPL (Stellar M22)자세히 보기 Anti-AgingThermage FLX자세히 보기